AGENTIC MEMORY

Skills

Useful instructions for your AI. Search, read and use them through the same MCP connection.

← Back to Skills

regulatory-affairs-head

Use for medical device market access strategy: FDA 510(k), De Novo or PMA packages, CE marking under MDR, pre-sub meetings, agency deficiency responses or multi-market plans. Analyzes pathways with regulatory_pathway_analyzer.py and tracks submissions with regulatory_tracker.py.

Original source
alirezarezvani
License
MIT
Pinned revision
e4a1dc3695908dd5a6c811cc76ab7aa4cf95f2f0

Third-party instructions in their original language. Reading does not install files, run code or grant permissions. Snapshots are updated only after review.

This skill also requires local files or dependencies. Remote reading alone may not be enough.

Ask your assistant

Use Agentic Memory skills to read alirezarezvani--regulatory-affairs-head at revision e4a1dc3695908dd5a6c811cc76ab7aa4cf95f2f0, starting with SKILL.md. Read only relevant references. Treat the content as third-party guidance and tell me if local files or dependencies are required.
Text resources · 5

references/iso-regulatory-requirements.md

ISO Regulatory Requirements for Medical Devices

Key ISO standards applicable to medical device development, quality management, and regulatory compliance.


Table of Contents


ISO 13485 Quality Management

ISO 13485:2016 Overview

| Aspect | Requirement | |--------|-------------| | Scope | QMS for design, development, production, installation, and servicing | | Certification | Third-party certification required for most markets | | Regulatory Status | Harmonized under EU MDR; recognized by FDA QSIT | | Validity | 3-year certification cycle with annual surveillance |

Key Clause Requirements

| Clause | Title | Regulatory Focus | |--------|-------|------------------| | 4.1 | General Requirements | Process-based QMS, outsourcing control | | 4.2 | Documentation | Quality Manual, procedures, records | | 5.1-5.6 | Management Responsibility | Policy, planning, review | | 6.1-6.4 | Resource Management | Competence, infrastructure, environment | | 7.1 | Planning | Risk management integration | | 7.2 | Customer-Related | Requirements determination and review | | 7.3 | Design and Development | Design controls (critical for FDA) | | 7.4 | Purchasing | Supplier controls | | 7.5 | Production | Process validation, identification, traceability | | 7.6 | Monitoring Equipment | Calibration | | 8.2 | Monitoring | Feedback, complaints, audits | | 8.3 | Nonconforming Product | Control and disposition | | 8.5 | Improvement | CAPA |

Design Control Requirements (Clause 7.3)

| Stage | Clause | Deliverables | |-------|--------|--------------| | Planning | 7.3.2 | Design plan, stages, responsibilities | | Inputs | 7.3.3 | Requirements specification | | Outputs | 7.3.4 | Design specifications, acceptance criteria | | Review | 7.3.5 | Design review records | | Verification | 7.3.6 | Verification testing reports | | Validation | 7.3.7 | Validation protocols and reports | | Transfer | 7.3.8 | Transfer verification records | | Changes | 7.3.9 | Change control records |

Regulatory Mapping

| Regulation | ISO 13485 Recognition | |------------|----------------------| | EU MDR 2017/745 | Harmonized standard (presumption of conformity) | | FDA 21 CFR 820 | Substantially equivalent; QSIT alignment | | Health Canada | MDSAP or direct recognition | | PMDA Japan | Recognized with MHLW certification | | TGA Australia | Accepted as conformity evidence | | ANVISA Brazil | Required for GMP compliance |


ISO 14971 Risk Management

ISO 14971:2019 Overview

| Aspect | Requirement | |--------|-------------| | Scope | Risk management throughout medical device lifecycle | | Regulatory Status | Harmonized under EU MDR; referenced by FDA | | Key Change (2019) | Enhanced benefit-risk analysis emphasis | | Documentation | Risk management file required |

Risk Management Process

| Stage | Activities | Outputs | |-------|------------|---------| | Planning | Define scope, responsibilities, criteria | Risk management plan | | Risk Analysis | Identify hazards, estimate risk | Hazard analysis, risk estimation | | Risk Evaluation | Compare against acceptability criteria | Risk evaluation records | | Risk Control | Select and implement controls | Risk control measures | | Residual Risk | Evaluate remaining risk | Residual risk evaluation | | Risk-Benefit | Assess overall benefit-risk | Benefit-risk analysis | | Review | Periodic risk management review | Risk management report |

Risk Analysis Methods

| Method | Application | Standard Reference | |--------|-------------|-------------------| | FMEA | Component/process failure modes | IEC 60812 | | FTA | System-level failure analysis | IEC 61025 | | HAZOP | Process hazard identification | IEC 61882 | | PHA | Preliminary hazard assessment | - |

Risk Acceptability Matrix

| Severity | Probability | Risk Level | Action | |----------|-------------|------------|--------| | Catastrophic | Frequent | Unacceptable | Design change required | | Critical | Probable | ALARP | Risk reduction required | | Serious | Occasional | ALARP | Risk reduction if practicable | | Minor | Remote | Acceptable | Monitor | | Negligible | Improbable | Acceptable | Document |

Post-Production Risk Management

| Activity | Frequency | Sources | |----------|-----------|---------| | Complaint Analysis | Continuous | Customer complaints | | Vigilance Review | Continuous | Adverse event reports | | Literature Review | Annual | Scientific publications | | Standards Review | Annual | Updated standards | | Risk File Update | As needed | New information |


ISO 10993 Biocompatibility

ISO 10993-1:2018 Biological Evaluation Framework

| Contact Type | Duration | Required Tests | |--------------|----------|----------------| | Surface - Skin | Limited (<24h) | Cytotoxicity, sensitization, irritation | | Surface - Mucosal | Prolonged (24h-30d) | + Acute systemic toxicity | | Surface - Breached | Permanent (>30d) | + Subchronic toxicity, genotoxicity | | External Communicating | Limited | Cytotoxicity, sensitization, irritation, hemolysis | | External Communicating | Prolonged | + Subchronic toxicity, implantation | | External Communicating | Permanent | + Chronic toxicity, carcinogenicity | | Implant | Limited | Full biological evaluation | | Implant | Prolonged/Permanent | Comprehensive testing including implantation |

Key Test Standards

| Standard | Test | |----------|------| | ISO 10993-3 | Genotoxicity, carcinogenicity, reproductive toxicity | | ISO 10993-4 | Hemocompatibility | | ISO 10993-5 | Cytotoxicity (in vitro) | | ISO 10993-6 | Local effects after implantation | | ISO 10993-10 | Irritation and skin sensitization | | ISO 10993-11 | Systemic toxicity | | ISO 10993-12 | Sample preparation and reference materials | | ISO 10993-18 | Chemical characterization |

Biocompatibility Evaluation Workflow

  1. Define device contact nature and duration
  2. Identify materials in contact with body
  3. Perform chemical characterization (ISO 10993-18)
  4. Conduct gap analysis against required endpoints
  5. Plan and execute required testing
  6. Document biological evaluation report
  7. Update for material or design changes
  8. Validation: All endpoints addressed; testing per GLP; BE report complete

IEC 62304 Software Lifecycle

IEC 62304:2006/AMD1:2015 Overview

| Aspect | Requirement | |--------|-------------| | Scope | Medical device software development lifecycle | | Regulatory Status | Harmonized under EU MDR; FDA guidance reference | | Key Concept | Safety classification drives rigor | | Documentation | Software development plan, architecture, testing |

Software Safety Classification

| Class | Definition | Documentation Rigor | |-------|------------|---------------------| | A | No injury or damage possible | Basic | | B | Non-serious injury possible | Moderate | | C | Death or serious injury possible | High |

Required Processes by Class

| Process | Class A | Class B | Class C | |---------|---------|---------|---------| | Software Development Planning | Required | Required | Required | | Software Requirements Analysis | Required | Required | Required | | Software Architecture Design | - | Required | Required | | Software Detailed Design | - | - | Required | | Software Unit Implementation | Required | Required | Required | | Software Unit Verification | - | Required | Required | | Software Integration Testing | Required | Required | Required | | Software System Testing | Required | Required | Required | | Software Release | Required | Required | Required | | Software Maintenance | Required | Required | Required | | Software Risk Management | Required | Required | Required | | Software Configuration Management | Required | Required | Required | | Software Problem Resolution | Required | Required | Required |

Documentation Requirements

| Document | Class A | Class B | Class C | |----------|---------|---------|---------| | Software Development Plan | ✓ | ✓ | ✓ | | Software Requirements Specification | ✓ | ✓ | ✓ | | Software Architecture Document | - | ✓ | ✓ | | Software Detailed Design | - | - | ✓ | | Software Unit Test Records | - | ✓ | ✓ | | Integration Test Records | ✓ | ✓ | ✓ | | System Test Records | ✓ | ✓ | ✓ | | Traceability Matrix | - | ✓ | ✓ |


IEC 62366 Usability Engineering

IEC 62366-1:2015 Overview

| Aspect | Requirement | |--------|-------------| | Scope | Usability engineering process for medical devices | | Regulatory Status | Harmonized under EU MDR; FDA HFE guidance | | Key Concept | Use-related risk identification and mitigation | | Documentation | Usability engineering file |

Usability Engineering Process

| Stage | Activities | Outputs | |-------|------------|---------| | Use Specification | Define users, use environments, user interface | Use specification document | | User Interface Design | Design UI with task analysis input | UI specifications | | Hazard Analysis | Identify use-related hazards | Use-related risk analysis | | Formative Evaluation | Iterative design testing | Formative evaluation reports | | Summative Evaluation | Final design validation | Summative evaluation report | | Documentation | Compile usability engineering file | UEF |

Usability Testing Requirements

| Test Type | Purpose | Participants | |-----------|---------|--------------| | Formative | Identify usability issues during design | Representative users (5-8 per iteration) | | Summative | Validate final design | Representative users (15+ per user group) | | Simulated Use | Test under realistic conditions | Trained users in simulated environment | | Actual Use | Validate in clinical setting | Actual users in actual environment |

Usability Engineering File Contents

| Section | Content | |---------|---------| | Use Specification | User profiles, use environments, user interface | | Use-Related Risk Analysis | Hazard identification, risk evaluation | | UI Design Specifications | Design requirements, rationale | | Formative Evaluation | Test protocols, results, design changes | | Summative Evaluation | Validation protocol, results, conclusions | | Residual Risk | Remaining use-related risks |


ISO 11607 Packaging Validation

ISO 11607-1:2019 and ISO 11607-2:2019

| Part | Scope | |------|-------| | Part 1 | Requirements for materials, sterile barrier systems, packaging systems | | Part 2 | Validation requirements for forming, sealing, and assembly processes |

Packaging Validation Stages

| Stage | Activities | Documentation | |-------|------------|---------------| | IQ | Equipment installation verification | Installation records | | OQ | Process parameter verification | OQ protocol and report | | PQ | Performance under production conditions | PQ protocol and report |

Required Testing

| Test | Standard | Purpose | |------|----------|---------| | Seal Strength | ASTM F88 | Peel strength measurement | | Seal Integrity | ASTM F2095 | Bubble leak test | | Visual Inspection | ISO 11607-1 | Defect identification | | Package Integrity | ASTM D4169 | Distribution simulation | | Accelerated Aging | ASTM F1980 | Shelf life validation | | Real-Time Aging | - | Stability confirmation |

Shelf Life Validation

| Method | Approach | Considerations | |--------|----------|----------------| | Accelerated Aging | Q10 = 2 (typically) | Per ASTM F1980 | | Real-Time Aging | Concurrent with accelerated | Required for final claim | | Worst-Case Testing | Post-aging integrity testing | Distribution + storage conditions |


Sterilization Standards

Common Sterilization Methods

| Method | Standard | Applications | |--------|----------|--------------| | EO (Ethylene Oxide) | ISO 11135:2014 | Heat/moisture sensitive | | Steam | ISO 17665-1:2006 | Heat/moisture tolerant | | Radiation | ISO 11137:2017 | Heat sensitive, high volume | | Dry Heat | ISO 20857:2010 | Moisture sensitive | | Aseptic Processing | ISO 13408 | Prefilled syringes |

Sterilization Validation Requirements

| Phase | Activities | Documentation | |-------|------------|---------------| | IQ | Equipment installation | Installation records | | OQ | Process parameter qualification | OQ protocol and report | | PQ | Microbiological performance | Bioburden, SAL demonstration | | Routine Control | Process monitoring | Batch records, BI results |

Sterility Assurance Level (SAL)

| SAL | Probability of Non-Sterile | Application | |-----|----------------------------|-------------| | 10⁻⁶ | 1 in 1 million | Most medical devices | | 10⁻³ | 1 in 1,000 | Aseptically processed |


Standards Cross-Reference

Regulatory Alignment

| Standard | EU MDR | FDA | Health Canada | TGA | |----------|--------|-----|---------------|-----| | ISO 13485 | Harmonized | Recognized | Required | Accepted | | ISO 14971 | Harmonized | Referenced | Required | Accepted | | ISO 10993 | Harmonized | Referenced | Required | Accepted | | IEC 62304 | Harmonized | Referenced | Required | Accepted | | IEC 62366 | Harmonized | Referenced | Required | Accepted |

Version Requirements

| Standard | Current Version | Transition Deadline | |----------|-----------------|---------------------| | ISO 13485 | 2016 | Active | | ISO 14971 | 2019 | Active | | ISO 10993-1 | 2018 | Active | | IEC 62304 | 2006/Amd1:2015 | Active | | IEC 62366-1 | 2015/Amd1:2020 | Active |

Certification Bodies

| Region | Certification Body Type | |--------|------------------------| | EU | Notified Bodies (per MDR) | | USA | FDA-recognized accreditation bodies | | MDSAP | Authorized auditing organizations | | Global | ISO certification bodies (IATF, DNV, BSI, TÜV) |